| scholarly article | Q13442814 |
| P2093 | author name string | Roberts R | |
| Levine M | |||
| Chambers S | |||
| Meyer R | |||
| Walker I | |||
| Boshkov L | |||
| Heddle NM | |||
| Klama L | |||
| O'Hoski P | |||
| Podlosky L | |||
| P2860 | cites work | Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions | Q40748675 |
| P433 | issue | 3 | |
| P921 | main subject | randomized controlled trial | Q1436668 |
| P304 | page(s) | 231-238 | |
| P577 | publication date | 1999-03-01 | |
| P1433 | published in | Transfusion | Q15758500 |
| P1476 | title | A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets | |
| P478 | volume | 39 |
| Q40570953 | A prospective, randomized clinical trial of universal WBC reduction |
| Q40579927 | A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets |
| Q41655074 | A retrospective observational study to assess adverse transfusion reactions of patients with and without prior transfusion history |
| Q24186913 | A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q44059748 | Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial |
| Q50526083 | Adhesive interaction between peripheral blood mononuclear cells and activated platelets in the presence of anti-human leukocyte antigen Class I alloantibody causes production of IL-1β and IL-8. |
| Q34659761 | Adverse events related to blood transfusion |
| Q43092210 | Allergic agonists in apheresis platelet products are associated with allergic transfusion reactions |
| Q40594585 | Analysis of 516 reports of reactions after the transfusion of labile blood products |
| Q33366635 | Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial |
| Q37012096 | Atopic predisposition of recipients in allergic transfusion reactions to apheresis platelets |
| Q37988224 | Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update |
| Q50506735 | Comparative in vitro evaluation of apheresis platelets stored with 100% plasma versus bicarbonated Ringer's solution with less than 5% plasma. |
| Q24187751 | Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q83314815 | Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage |
| Q40584632 | Cytokine release in febrile non-haemolytic red cell transfusion reactions |
| Q37593318 | Desensitization in allergic transfusion reactions: evidence from the Trial to Reduce Alloimmunization to Platelets |
| Q24186359 | Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q40277127 | Effects of prestorage vs poststorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to platelets |
| Q41789969 | Evaluation of White Blood Cell- and Platelet-Derived Cytokine Accumulation in MIRASOL-PRT-Treated Platelets |
| Q40547941 | Evaluation of adherence to the regulations for declaration of notification of transfusion reactions with fever and chills. A study of the Association Inter-Régionale du Sud-Est d'Hémovigilance (AIRSEH) |
| Q34405086 | Evidence-based recommendations for the use of WBC-reduced cellular blood components |
| Q40179540 | Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S. elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011-2012. |
| Q47552365 | From cytokines to pragmatic designs: changing paradigms |
| Q50551784 | Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions. |
| Q33432190 | I am the 9%: Making the case for whole-blood platelets |
| Q44036356 | In vitro safety profile of G-CSF-mobilized whole blood after storage for 7 days in an infusable-grade L15 medium |
| Q33381674 | Introduction of platelet additive solution in platelet concentrates: towards a decrease of blood transfusion reactions |
| Q33835138 | Leukocyte reduction of blood components: public policy and new technology |
| Q53850593 | Leukoreduction in the setting of open heart surgery: a prospective cohort-controlled study. |
| Q35131637 | Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. |
| Q50252158 | Mitochondrial damage-associated molecular patterns as potential proinflammatory mediators in post-platelet transfusion adverse effects |
| Q33361167 | Optimizing platelet transfusion therapy |
| Q34279813 | Pilot analysis of cytokines levels in stored granulocyte-colony-stimulating factor-mobilized peripheral blood stem cell concentrates |
| Q50521947 | Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction. |
| Q56505470 | Platelet transfusions |
| Q40577692 | Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction |
| Q24245960 | Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation |
| Q24197779 | Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation |
| Q50675488 | Proteomic analysis of supernatant from pooled buffy-coat platelet concentrates throughout 7-day storage. |
| Q33982899 | Recognition, Investigation and Management of Acute Transfusion Reactions: Consensus guidelines for Oman |
| Q40543308 | Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction |
| Q37012102 | Scratching the surface of allergic transfusion reactions |
| Q37040030 | Sporadic leukoreduction filter failure during red blood cell component preparation: beware of rapid filtration |
| Q51205261 | Storage of platelet-rich plasma-derived platelet concentrate pools in plasma and additive solution. |
| Q50469791 | Storage of volume-reduced washed platelets in M-sol additive solution for 7 days. |
| Q34116488 | The case against universal WBC reduction (and for the practice of evidence-based medicine). |
| Q34285935 | The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. |
| Q34231829 | The hazards of blood transfusion in historical perspective |
| Q78833819 | The influence of platelet additive solutions on cytokine levels and complement activation in platelet concentrates during storage |
| Q35813075 | The top ten list of randomized controlled trials in transfusion medicine |
| Q40561269 | Three years of haemovigilance in a general university hospital |
| Q38852062 | Transfusion premedication practices among pediatric health care practitioners in Canada: results of a national survey |
| Q36831189 | Transfusion premedications: a growing practice not based on evidence |
| Q34247853 | Universal WBC reduction: the case for and against |
Search more.